/

Società

NM

Società

NMS GROUP S.P.A.

Di cosa scriviamo

ArteCulturaOncologiaSaluteSanità

33 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

28/04/2025

Salute

Oncologia

Sanità

Nerviano Medical Sciences Initiates Combination Phase 1 Trials of NMS-293 in Relapsed Small Cell Lung and BRCA Wild-Type Ovarian Cancers - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

31/03/2025

Salute

Oncologia

Sanità

Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

21/02/2025

Arte

Cultura

Archeologia

Legge/Diritto

CPhI Japan 2025 - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

19/02/2025

Arte

Cultura

Legge/Diritto

Aerospazio

DCAT WEEK 2025 - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

10/02/2025

Salute

Oncologia

Sanità

PARP1 publications - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

31/01/2025

Salute

Oncologia

Sanità

Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

22/01/2025

Salute

Oncologia

Sanità

Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

13/01/2025

Salute

Oncologia

Sanità

Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

07/01/2025

Salute

Oncologia

Sanità

Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Press Release cover image

25/11/2024

Salute

Sanità

Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results - NMS Group

Fonte

NMS GROUP S.P.A.

1,00

0

Seguaci

0

Compatibilità

0